Comparative Pharmacology
Head-to-head clinical analysis: NIVESTYM versus RELEUKO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIVESTYM versus RELEUKO.
NIVESTYM vs RELEUKO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
Recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates proliferation, differentiation, and activation of neutrophil progenitor cells.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days until absolute neutrophil count reaches 10,000/mm³ after nadir; or 5 mcg/kg subcutaneously once daily for 5 days for mobilization of peripheral blood progenitor cells.
5 mcg/kg subcutaneously once daily for up to 10 days or until neutrophil count >10,000/mcL after nadir.
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (subcutaneous) in healthy volunteers; in patients undergoing chemotherapy, half-life may be prolonged (up to 4-6 hours) due to neutrophil-mediated clearance.
Terminal half-life approximately 5.3 hours (range 4.5–6.2 hours) in adults with normal renal function.
Primarily renal (via degradation to peptides and amino acids); <1% excreted unchanged. Biliary/fecal elimination is negligible.
Primarily renal (approximately 70% as intact drug). Minor biliary/fecal elimination (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor